Table 1.
Baseline patient characteristics of the entire cohort and of patients with genomic data.
| All patients n = 150 | Patients with genomic data n = 91 | |
|---|---|---|
| Age, median (range) | 50 (27–79) | 51 (27–76) |
| HISTOLOGICAL GRADE | ||
| Grade 2 | 47 (31.3%) | 33 (36.3%) |
| Grade 3 | 101 (67.3%) | 57 (62.6%) |
| Not evaluable | 2 (1.3%) | 1 (1.1%) |
| TUMOR STAGE | ||
| T1 | 9 (6.0%) | 7 (7.8%) |
| T2 | 97 (64.7%) | 55 (61.1%) |
| T3 | 15 (10.0%) | 8 (8.9%) |
| T4b | 16 (10.6 %) | 10 (11.1%) |
| T4d | 13 (8.7%) | 10 (11.1%) |
| NODAL STATUS | ||
| N0 | 34 (22.5%) | 18 (20%) |
| N1 | 90 (59.6%) | 57 (63.3%) |
| N2 | 15 (9.9%) | 10 (11.1%) |
| N3 | 11 (7.3%) | 5 (5.6%) |
| HORMONAL RECEPTOR STATUS | ||
| ER+ PR+ | 56 (37.4%) | 36 (39.6%) |
| ER+ PR– | 22 (14.4%) | 11(12.1%) |
| ER– PR+ | 2 (1.2%) | 2 (2.2%) |
| ER– PR– | 70 (47.0%) | 42 (46.1%) |
| Ki67 | ||
| <20 | 27 (18.0%) | 18 (19.8%) |
| ≥20 | 119 (79.3%) | 73 (80.2%) |
| Not evaluable | 4 (2.7%) | |
ER, estrogen receptor; PR, progesterone receptor.